Anivive Lifesciences, a software-driven pet pharmaceutical company headquartered in Long Beach, California, announced on Valentine’s Day the successful completion of its field study to evaluate the safety and effectiveness of Laverdia-CA1 verdinexor tablets in dogs with lymphoma. The randomized, placebo-controlled, double-masked study conducted at 12 clinical trial sites across the USA enrolled 150 dogs selected from more than 700 applicants using AniviveTrial. The company said the final study site was closed on December 12, marking the end of patient treatment and data collection.
Also Read: New diagnostic panel helps detect canine lymphoma early
A press release from Anivive Lifesciences said the completion of the field study represents a key milestone in its mission to deliver innovative cancer treatments to companion animals, such as this first-in-class XP01 blocker.
With data collection done, the company has locked the database to begin statistical analysis, and the results are expected in the coming months. Anivive aims to submit the effectiveness technical section for regulatory review in the summer. All other major technical sections of the new animal drug application have been deemed complete by the U.S. Food and Drug Administration, which gave conditional approval in 2021 for the use of Laverdia-CA1 to treat lymphoma in dogs.
Also Read: Groundbreaking study to use AI to help cancer detection in dogs
According to Anivive Lifesciences, the drug has the potential to be a cutting-edge oral treatment option for canine lymphoma, offering a non-invasive approach for veterinary oncology patients. “The completion of our critical study for Laverdia-CA1 marks a major milestone in bringing forward an innovative therapy for canine lymphoma,” said Dylan Balsz, chief executive officer of Anivive. “We are excited to analyze the data and move closer to making an oral treatment option available for dogs living with this challenging disease.”
Anivive Lifesciences expanded its portfolio of veterinary services in 2024 by offering specialty pathology services and a next-generation tumour genomic sequencing test with its SearchLight DNA, which was developed in partnership with TGen, the Translational Genomics Research Institute, part of City of Hope, one of the largest and most advanced cancer research and treatment organizations in the USA.
SOURCE: PR Newswire
